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these observational studies need to be conﬁrmed in large randomized
clinical trials for chocolate intake.
References
[1] Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010
update: a report from the AmericanHeart Association. Circulation 2010;121:e46–e215.
[2] Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases:
part I: general considerations, the epidemiologic transition, risk factors, and impact of
urbanization. Circulation 2001;104:2746–53.
[3] Desch S, Schmidt J, Kobler D, et al. Effect of cocoa products on blood pressure:
systematic review and meta-analysis. Am J Hypertens 2010;23:97–103.
[4] Faridi Z, Njike VY, Dutta S, Ali A, Katz DL. Acute dark chocolate and cocoa ingestion
and endothelial function: a randomized controlled crossover trial. Am J Clin Nutr
2008;88:58–63.
[5] Heiss C, Kleinbongard P, Dejam A, et al. Acute consumption of ﬂavanol-rich cocoa
and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol
2005;46:1276–83.
[6] Grassi D, Lippi C, Necozione S, Desideri G, Ferri C. Short-term administration of dark
chocolate is followed by a signiﬁcant increase in insulin sensitivity and a decrease in
blood pressure in healthy persons. Am J Clin Nutr 2005;81:611–4.
[7] Buitrago-Lopez A, Sanderson J, Johnson L, et al. Chocolate consumption and
cardiometabolic disorders: systematic review and meta-analysis. BMJ 2011;343:
d4488.
[8] Greenland S, Longnecker MP. Methods for trend estimation from summarized dose–
response data, with applications to meta-analysis. Am J Epidemiol 1992;135:1301–9.
[9] Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of
summarized dose–response data. Stata J 2006;6:40–57.
[10] Buijsse B, Feskens EJ, Kok FJ, Kromhout D. Cocoa intake, blood pressure, and
cardiovascular mortality: the Zutphen Elderly Study. Arch Intern Med
2006;166:411–7.
[11] Mink PJ, Scrafford CG, Barraj LM, et al. Flavonoid intake and cardiovascular disease
mortality: a prospective study in postmenopausal women. Am J Clin Nutr
2007;85:895–909.
[12] Janszky I, Mukamal KJ, Ljung R, Ahnve S, Ahlbom A, Hallqvist J. Chocolate
consumption and mortality following a ﬁrst acute myocardial infarction: the
Stockholm Heart Epidemiology Program. J Intern Med 2009;266:248–57.
[13] Buijsse B, Weikert C, Drogan D, Bergmann M, Boeing H. Chocolate consumption in
relation to blood pressure and risk of cardiovascular disease in German adults. Eur
Heart J 2010;31:1616–23.
[14] Lewis JR, Prince RL, Zhu K, Devine A, Thompson PL, Hodgson JM. Habitual
chocolate intake and vascular disease: a prospective study of clinical outcomes in
older women. Arch Intern Med 2010;170:1857–8.
[15] Conen D, Chiuve SE, Everett BM, Zhang SM, Buring JE, Albert CM. Caffeine
consumption and incident atrial ﬁbrillation in women. Am J Clin Nutr
2010;92:509–14.
[16] Mostofsky E, Levitan EB, Wolk A, Mittleman MA. Chocolate intake and incidence of
heart failure: a population-based prospective study of middle-aged and elderly
women. Circ Heart Fail 2010;3:612–6.
[17] Djousse L, Hopkins PN, North KE, Pankow JS, Arnett DK, Ellison RC. Chocolate
consumption is inversely associated with prevalent coronary heart disease: the
National Heart, Lung, and Blood Institute Family Heart Study. Clin Nutr
2011;30:182–7.
[18] Larsson SC, Virtamo J, Wolk A. Chocolate consumption and risk of stroke inwomen. J
Am Coll Cardiol 2011;58:1828–9.
[19] Larsson SC, Virtamo J, Wolk A. Chocolate consumption and risk of stroke: a
prospective cohort of men and meta-analysis. Neurology 2012;79:1223–9.
0167-5273 © 2012 Elsevier Ireland Ltd.
http://dx.doi.org/10.1016/j.ijcard.2012.12.036
Increased mTORC1 activity contributes to atherosclerosis in
apolipoprotein E knockout mice and in vascular smooth muscle cells
Kun Ling Ma a, Jing Liu a, Chang Xian Wang b, Jie Ni a, Yang Zhang a, Yu Wu a, Lin Li Lv a,
Xiong Zhong Ruan c, Bi Cheng Liu a,⁎
a Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing City, Jiangsu Province, China
b Department of Infection Management, Zhong Da Hospital, Southeast University School of Medicine, Nanjing City, Jiangsu Province, China
c Centre for Nephrology, University College London (UCL) Medical School, Royal Free Campus, UK
a r t i c l e i n f o
Article history:
Received 30 March 2013
Accepted 30 March 2013
Available online 23 August 2013
Keywords:
Inﬂammation
Mammalian target of rapamycin
LDL receptor pathway
Atherosclerosis
Inﬂammation and dyslipidaemia play crucial, synergistic roles in the
deterioration that occurs during the progression of atherosclerosis [1,2].
However, the exact mechanisms of atherosclerosis have not been
completely elucidated. Mammalian target of rapamycin (mTOR) is a
serine/threonine kinase that plays important roles in regulating cellular
homeostasis and metabolism. The mTOR protein nucleates at least two
distinctmulti-protein complexes, namelymTORcomplex1(mTORC1)and
mTOR complex 2 (mTORC2) [3]. The mTORC1 integrates stimulating
signals and then phosphorylates p70 S6 kinase 1 (S6K1) and eukaryotic
initiation factor 4E-binding protein 1 (4EBP1). This activity results in cell
growth, activation of translation, and ribosome biosynthesis [4–6].
Rapamycin and its analogues only inhibit the activity of mTORC1 [3].
mTORC2 primarily modulates cell survival, cell polarity, cytoskeletal
organisation, and activity of the aldosterone-sensitive sodium channel [7].
Our previous studies demonstrated that inﬂammation disrupts the
feedback regulation of the low density lipoprotein receptor (LDLr) and
3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGR) to increase
intracellular cholesterol uptake and biosynthesis, which results in
intracellular lipid accumulation and foam cell formation. However, these
effects were blocked by rapamycin treatment through the inhibition of
SREBP-2 expression and a decrease in SCAP/SREBP-2 complex transloca-
tion from the ER to the Golgi [1,8]. These ﬁndings suggest that the mTOR
pathwaymaybe involved in thedisruptionof cholesterol homeostasis that
occurs in response to inﬂammatory stress. Therefore, the present study
was undertaken to investigate the role of the mTOR pathway in the
progression of atherosclerosis in both apolipoprotein E knockout (ApoE
KO)mice and vascular smoothmuscle cells (VSMCs) under inﬂammatory
stress.
To induce inﬂammation, we used subcutaneous injection of 10%
casein inmale ApoE KOmice and lipopolysaccharide stimulation in rat
VSMCs. ApoE KO mice with a C57BL/6 genetic background were
studied under protocols approved by the Ethical Committee of
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Southeast University and followed the latest version of the Declaration
of Helsinki. Eight-week-old ApoE KO mice were randomly assigned to
daily subcutaneous injections of 0.5 ml PBS (control), 8 mg/kg/q.o.d
rapamycin (Rapa),10% casein (casein), or rapamycin plus casein (casein
plus Rapa). The mice were fed the Western diet containing 21% fat and
0.15% cholesterol for 8 weeks.
Results showed that inﬂammation increased lipid accumulation
in aortas of ApoE KO mice and in VSMCs (Fig. 1A and B), which were
correlated with increased expressions of LDLr, sterol regulatory
element-binding protein (SREBP) cleavage-activating protein (SCAP),
and SREBP-2 as well as with enhanced translocation of SCAP/SREBP-2
complex from endoplasmic reticulum (ER) to Golgi. Furthermore,
inﬂammation increased both the percentage of cells in the S phase
of cell cycle and protein expressions of the phosphorylated forms of
retinoblastoma tumour suppressor protein (Rb), mTOR, eukaryotic
initiation factor 4E-binding protein 1 (4EBP1), and P70 S6 kinase. After
treatment with rapamycin or mTOR siRNA, the activity of mTOR
pathway was blocked. Interestingly, the expression levels of LDLr,
SCAP, andSREBP-2and the translocationof SCAP/SREBP-2 complex from
the ER to the Golgi in treated VSMCs were decreased even in the
presence of inﬂammatory stress (Fig. 2A–D).
Our ﬁndings demonstrate for the ﬁrst time that inﬂammation
disrupts LDLr feedback regulation through the activation of mTOR
pathway. IncreasedmTORC1 activity was found to upregulate SREBP-2-
mediated cholesterol uptake through Rb phosphorylation.
We thank Professor Yaxi Chen from Chong Qing University for
providing us big support in the experiments. This work was supported
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Fig. 1. Inhibition of themTOR pathway decreased the lipid accumulation induced by inﬂammation in vivo and in vitro. ApoE KOmicewere fed theWestern diet for eight weeks and
received either no treatment (Control, I and V) or were treated by injectionwith 10% casein (Casein, II and VI), 8 mg/kg/q.o.d rapamycin (Rapa, III and VII) or rapamycin plus casein
(Rapa plus Casein, IV and VIII). (A) The lipid accumulation in the aorta in ApoE KOmice was examined by staining with H&E (I–IV, 400×magniﬁcation) and (B) Oil Red O (V–VIII,
400× magniﬁcation). An area populated with foam cells is indicated by an arrow in II.
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Fig. 2. mTOR inhibition downregulated the expression of the LDLr pathway induced by inﬂammation in vivo and in vitro. ApoE KOmicewere fed theWestern diet for eight weeks and received
either no treatment (Control, I) or were treated by injection with 10% casein (Casein, II), 8 mg/kg/q.o.d rapamycin (Rapa, III) or rapamycin plus casein (Rapa plus Casein, IV). (A) The protein
expression level of LDLr in ApoE KO mice was examined by immunostaining of cross-sections of the aorta. Brown staining indicates areas of LDLr expression (200× magniﬁcation). (B) The
translocation of SCAP escorting SREBP-2 from the ER to theGolgiwas checked by immunoﬂuorescent staining using cross-sections of the aorta. The immunoﬂuorescent signalswere detected by
confocal microscopy. (C & D) VSMCswere incubated for 24 h either in serum-freemedium (Control) or serum-free medium containing 25 μg/ml of lipopolysaccharide (LPS) alone,10 ng/ml of
rapamycin alone (Rapa) or 25 μg/ml of LPS plus 10 ng/ml of rapamycin (LPS plus Rapa). The protein expression of LDLr, nuclear SREBP-2 (nSREBP-2), and SCAP were determined by Western
blotting. The histogram shows themeans ± SD of the densitometric scans of the LDLr, SREBP-2 and SCAP protein bands from three experiments following normalisation by comparisonwithβ-
actin. *p b 0.05 vs. Control; **p b 0.001 vs. Control.
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The diagnosis of STEMI is based classically on a “cross-sectional”
examination of the presenting ECG at ﬁrst medical contact. This approach
may bemodiﬁed as patients can now record ECG strips on an iPhone [1]. In
the near future, multi-electrode recordings with electrodes embedded on a
pad or a vest which the patient places or wears over the chest may provide
“longitudinal” information to the evolutionary ECG changes of STEMI prior
to ﬁrst medical contact. A recent article forecasted that with Smart Phone
ECG monitoring the longitudinal ECG information will allow STEMI to be
categorized on a gray-scale ranging from large rapidly progressive STEMI to
small stuttering STEMI [1]. The next question is whether the Phone ECG
information also allows new treatment or self-therapy to be initiated prior
to ﬁrstmedical contact to help “abort” the progressive coronary thrombosis
causing the infarction.
The concept of “aborting” a STEMI has been around since the MITI trial
exploring the role of pre-hospital ﬁbrinolytic therapy [2]. In that trial,
treatment initiated within 70minutes of symptom onset was found to be
associated with lower mortality (1.2% vs 8.7%, P=0.04); smaller
scintigraphic infarct size (4.9% vs 11.2%, P b .001) and better ejection
fraction (53% vs 49%, P= 0.03) than later treatment.
Aborted STEMI originally refers to resolution of both ST elevation and
symptoms without biochemical evidence of myocyte necrosis. The latter
criterion is evolving with increasingly sensitive cardiac troponin biomarker
assays as compared to traditional cardiac enzyme measurements. From
2004 to 2007, 767 patients who presented with suspected STEMI to the
Mayo Clinic underwent a standard protocol for their reperfusion treatment
mandating serial blood draws at 0, 6, 12, 24 hours. Cardiac troponin T
(cTnT) was measured with the third-generation cTnT electrochemilumi-
nescence immunoassay. Two patients died early with incomplete serial
biomarkers data. The diagnosis of STEMI was conﬁrmed in the
remaining 765 patients, all exhibiting troponin T elevation N99th
percentile cut-off value. In contrast, Creatine kinase (CK) –MB levels
of ≥ upper limit of normal occurred in only 90% and CK≥ twice the
upper limits of normal occurred in 79% [3].
Using a deﬁnition of maximal CK≤ twice the upper limit of normal
coupled with typical evolutionary ECG changes of STEMI to diagnose
aborted infarction, the ASSENT-3 trial, using tenecteplase as the primary
agent forﬁbrinolysis, reported that 13.3%of 5470patients had their STEMI
aborted - 25%, 17%, 14%, 10.5% respectively among patients treated within
the ﬁrst hour, 1–2 hour, 2–3 hour and N 3 hours of symptom onset [4]
attesting to the importance of early therapy.
Fibrinolytic drugs can cause serious bleeding. In the early “minutes”
of coronary thrombosis and spontaneous lysis, often with vasoconstric-
tion worsening the occlusion, it is possible that other drugs which alter
coagulation or vasomotion may “restore the balance” and stop
thrombosis. Timely primary percutaneous coronary intervention (PCI)
is now accepted as the best treatment for STEMI. The current article
reviewswhether STEMI canbe abortedwithoutusingﬁbrinolytic therapy
Fig. 2 (continued).
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